Algernon Pharmaceuticals (AGNPF) News Today $0.05 0.00 (0.00%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF) Short Interest UpdateNovember 13, 2024 | americanbankingnews.comAlgernon Announces Warrant ExtensionNovember 4, 2024 | globenewswire.comAlgernon Pharmaceuticals Inc. (AGNPF)September 5, 2024 | finance.yahoo.comAlgernon Pharmaceuticals Inc Class ASeptember 1, 2024 | morningstar.comAlgernon Pharmaceuticals Announces Closing of Private PlacementAugust 20, 2024 | globenewswire.comAlgernon Pharmaceuticals Announces Increase to Private PlacementAugust 13, 2024 | globenewswire.comAlgernon Pharmaceuticals Announces Private PlacementAugust 7, 2024 | globenewswire.comAlgernon Pharmaceuticals Announces Closing of Private PlacementAugust 2, 2024 | globenewswire.comAlgernon Pharmaceuticals Announces Increase to Private PlacementJuly 31, 2024 | globenewswire.comAlgernon Pharmaceuticals Announces Private PlacementJuly 11, 2024 | globenewswire.comAlgernon Pharmaceuticals Engages ICP Securities Inc. for Automated Market Making ServicesMay 21, 2024 | globenewswire.comAlgernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024April 24, 2024 | globenewswire.comAlgernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar on April 16th, 2024April 11, 2024 | globenewswire.comDMT For Stroke Treatment: Algernon Sets Phase 2 Clinical Trial DesignApril 3, 2024 | msn.comAlgernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead AssetApril 1, 2024 | globenewswire.comAlgernon Pharmaceuticals Strikes Deal to Advance Ifenprodil in Chronic Cough TreatmentMarch 28, 2024 | finance.yahoo.comCanadian Investment Regulatory Organization Trading Halt - AGNMarch 27, 2024 | finance.yahoo.comCanadian Investment Regulatory Organization Trade Resumption - AGNMarch 27, 2024 | finance.yahoo.comAlgernon Pharmaceuticals closes $2M acquisition of its chronic cough research program by SeyltxMarch 27, 2024 | proactiveinvestors.comAlgernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity PositionMarch 27, 2024 | globenewswire.comAlgernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKDJanuary 31, 2024 | finance.yahoo.comAlgernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary FibrosisJanuary 11, 2024 | finance.yahoo.comAlgernon Pharmaceuticals Announces Increase to Private PlacementDecember 27, 2023 | finance.yahoo.comAlgernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLDNovember 30, 2023 | finance.yahoo.comSeyltx acquires Algernon's chronic cough research program for $2M and 20% stakeNovember 22, 2023 | msn.comAlgernon Pharmaceuticals Announces LOI for the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity PositionNovember 22, 2023 | finance.yahoo.comAlgernon Pharmaceuticals Inc. (AGN.CN)November 12, 2023 | uk.finance.yahoo.comAlgernon gets Japanese patent notice of allowance for treatment of NASH with RepirinastNovember 8, 2023 | msn.comAlgernon Pharmaceuticals Receives Japanese Patent Notice of Allowance for Treatment of NASH with RepirinastNovember 8, 2023 | finance.yahoo.comAlgernon Pharmaceuticals Inc Class A (AGN)September 9, 2023 | investing.comAlgernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD and NASHSeptember 6, 2023 | finance.yahoo.comDMT As A Treatment For Stroke? This Company Is Closer To Launching Its Phase 2 StudyAugust 8, 2023 | benzinga.comAlgernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke StudyAugust 8, 2023 | finance.yahoo.comAlgernon Pharmaceuticals Announces Private Placement and Issuance of Shares in Connection with Financial Advisory AgreementJuly 14, 2023 | finance.yahoo.comAlgernon Pharmaceuticals Engages Maxim Group to Explore Spin-Off of its Ifenprodil Phase 2 Chronic Cough Drug Development ProgramJune 27, 2023 | finance.yahoo.comAlgernon Pharmaceuticals to Present Phase 2 Ifenprodil Cough Data at the 2023 American Cough ConferenceJune 6, 2023 | finance.yahoo.comAlgernon Pharmaceuticals plans Phase 2 stroke and TBI study after successful DMT single dose studyJune 5, 2023 | finance.yahoo.comAlgernon Pharmaceuticals subsidiary completes DMT escalating dose studyJune 5, 2023 | proactiveinvestors.comAlgernon NeuroScience Announces Successful Completion of Highest Planned Single Dose in DMT Phase 1 Trial; Accelerates Plans for Phase 2 Stroke and TBI StudiesJune 5, 2023 | finance.yahoo.comAlgernon Pharmaceuticals receives Notice of Allowance from Japanese Patent Office for RepirinastMay 31, 2023 | proactiveinvestors.comAlgernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office for Repirinast and the Treatment of CKDMay 31, 2023 | finance.yahoo.comAlgernon Pharmaceuticals Announces Closing of Rights OfferingMay 5, 2023 | finance.yahoo.comIIROC Trading Halt - AGN.RTApril 27, 2023 | finance.yahoo.comAlgernon Pharmaceuticals Reminds Shareholders of Previously Announced Rights Offering and Approaching Cut Off Date and TimeApril 20, 2023 | finance.yahoo.comAlgernon Pharmaceuticals receives notice of allowance for US patent for drug Repirinast and NASHApril 18, 2023 | finance.yahoo.comAlgernon Pharma receives Notice of Allowance from US Patent and Trademark Office for RepirinastApril 17, 2023 | proactiveinvestors.comAlgernon Pharmaceuticals Announces Notice of Allowance for Method of Use U.S. Patent ApplicationApril 17, 2023 | finance.yahoo.comAlgernon NeuroScience reports successful second cohort dosing in DMT clinical studyApril 5, 2023 | finance.yahoo.comIntravenous DMT Therapy Seeks Ideal Dosage For Stroke And TBI TreatmentApril 4, 2023 | benzinga.comAlgernon Pharmaceuticals announces successful dosing of second cohort in Phase 1 DMT clinical studyApril 4, 2023 | proactiveinvestors.com Get Algernon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AGNPF and its competitors with MarketBeat's FREE daily newsletter. Email Address Breaking News: Tesla headed to $500… (Ad)That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. AGNPF Media Mentions By Week AGNPF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AGNPF News Sentiment▼0.980.47▲Average Medical News Sentiment AGNPF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AGNPF Articles This Week▼00▲AGNPF Articles Average Week Get Algernon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AGNPF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies 4Front Ventures News Today Allstar Health Brands News Today Alvotech News Today American Premium Mining News Today Anew Medical News Today Arno Therapeutics News Today AstraZeneca News Today AVVAA World Health Care Products News Today Basilea Pharmaceutica News Today biote News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:AGNPF) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Algernon Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Algernon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
